Literature DB >> 29046477

Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia.

Vincent A Jourdain1, Katharina A Schindlbeck1, Chris C Tang1, Martin Niethammer1,2, Yoon Young Choi1, Daniel Markowitz3, Amir Nazem1, Dominic Nardi4, Nicholas Carras4, Andrew Feigin1,2, Yilong Ma1, Shichun Peng1, Vijay Dhawan1, David Eidelberg1,2.   

Abstract

In a rodent model of Parkinson's disease (PD), levodopa-induced involuntary movements have been linked to striatal angiogenesis - a process that is difficult to document in living human subjects. Angiogenesis can be accompanied by localized increases in cerebral blood flow (CBF) responses to hypercapnia. We therefore explored the possibility that, in the absence of levodopa, local hypercapnic CBF responses are abnormally increased in PD patients with levodopa-induced dyskinesias (LID) but not in their nondyskinetic (NLID) counterparts. We used H215O PET to scan 24 unmedicated PD subjects (12 LID and 12 NLID) and 12 matched healthy subjects in the rest state under normocapnic and hypercapnic conditions. Hypercapnic CBF responses were compared to corresponding levodopa responses from the same subjects. Group differences in hypercapnic vasoreactivity were significant only in the posterior putamen, with greater CBF responses in LID subjects compared with the other subjects. Hypercapnic and levodopa-mediated CBF responses measured in this region exhibited distinct associations with disease severity: the former correlated with off-state motor disability ratings but not symptom duration, whereas the latter correlated with symptom duration but not motor disability. These are the first in vivo human findings linking LID to microvascular changes in the basal ganglia.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29046477      PMCID: PMC5846717          DOI: 10.1172/jci.insight.96411

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  31 in total

1.  Brain hemodynamic changes mediated by dopamine receptors: Role of the cerebral microvasculature in dopamine-mediated neurovascular coupling.

Authors:  Ji-Kyung Choi; Y Iris Chen; Edith Hamel; Bruce G Jenkins
Journal:  Neuroimage       Date:  2006-02-03       Impact factor: 6.556

2.  Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis.

Authors:  Asmaa M Teema; Sawsan A Zaitone; Yasser M Moustafa
Journal:  Neuropharmacology       Date:  2016-03-23       Impact factor: 5.250

3.  Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy.

Authors:  Brinda Desai Bradaric; Aditiben Patel; Julie A Schneider; Paul M Carvey; Bill Hendey
Journal:  J Neural Transm (Vienna)       Date:  2011-07-12       Impact factor: 3.575

4.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

5.  Changes in network activity with the progression of Parkinson's disease.

Authors:  Chaorui Huang; Chengke Tang; Andrew Feigin; Martin Lesser; Yilong Ma; Michael Pourfar; Vijay Dhawan; David Eidelberg
Journal:  Brain       Date:  2007-04-30       Impact factor: 13.501

6.  Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease.

Authors:  Chris C Tang; Kathleen L Poston; Vijay Dhawan; David Eidelberg
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

7.  Massive inborn angiogenesis in the brain scarcely raises cerebral blood flow.

Authors:  Johannes Vogel; Mathias Gehrig; Wolfgang Kuschinsky; Hugo H Marti
Journal:  J Cereb Blood Flow Metab       Date:  2004-08       Impact factor: 6.200

8.  Direct evidence for activity-dependent glucose phosphorylation in neurons with implications for the astrocyte-to-neuron lactate shuttle.

Authors:  Anant B Patel; James C K Lai; Golam M I Chowdhury; Fahmeed Hyder; Douglas L Rothman; Robert G Shulman; Kevin L Behar
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-26       Impact factor: 11.205

9.  Increased CSF biomarkers of angiogenesis in Parkinson disease.

Authors:  Shorena Janelidze; Daniel Lindqvist; Veronica Francardo; Sara Hall; Henrik Zetterberg; Kaj Blennow; Charles H Adler; Thomas G Beach; Geidy E Serrano; Danielle van Westen; Elisabet Londos; M Angela Cenci; Oskar Hansson
Journal:  Neurology       Date:  2015-10-28       Impact factor: 9.910

10.  The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.

Authors:  Roberto Cilia; Albert Akpalu; Fred Stephen Sarfo; Momodou Cham; Marianna Amboni; Emanuele Cereda; Margherita Fabbri; Patrick Adjei; John Akassi; Alba Bonetti; Gianni Pezzoli
Journal:  Brain       Date:  2014-07-17       Impact factor: 13.501

View more
  2 in total

1.  Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia.

Authors:  Renata P Lerner; Veronica Francardo; Koji Fujita; Zisis Bimpisidis; Vincent A Jourdain; Chris C Tang; Stephen L Dewey; Thomas Chaly; M Angela Cenci; David Eidelberg
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

2.  Transplantation of Human Neural Progenitor Cells (NPC) into Putamina of Parkinsonian Patients: A Case Series Study, Safety and Efficacy Four Years after Surgery.

Authors:  I Madrazo; O Kopyov; M A Ávila-Rodríguez; F Ostrosky; H Carrasco; A Kopyov; A Avendaño-Estrada; F Jiménez; E Magallón; C Zamorano; G González; T Valenzuela; R Carrillo; F Palma; R Rivera; R E Franco-Bourland; G Guízar-Sahagún
Journal:  Cell Transplant       Date:  2018-12-21       Impact factor: 4.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.